Averna Therapeutics

Delivering what's next in genetic medicine.

Watertown, United States · Founded 2022 · $82.0M raised

Employees
11–50
Founded
2022
Business Model
B2B
Total Funding
$82.0M
Last Round
$82.0M Series AJun 2024
Rounds
1

About

Averna Therapeutics (formerly Exsilio Therapeutics) is a biotechnology company developing RNA/lipid nanoparticle (LNP)-based genomic medicines designed to durably insert any gene or genetic instruction of interest into cells. The company's platform leverages site-specific retrotransposons — nature's precision gene insertion system — to safely integrate large sets of genetic instructions at safe harbor genomic locations without disrupting cell function. Averna's all-RNA system, delivered by LNPs, aims to expand the reach of genetic medicines beyond what viral approaches can achieve, broadening addressable diseases and patient populations. The company was recognized as a 2025 Endpoints 11 Most Promising Biotech.

Summary

Averna Therapeutics is a Life Sciences company based in Watertown, United States, founded in 2022. It has raised $82.0M in total across 1 round, most recently a $82.0M Series A round in Jun 2024. Investors include Novartis Venture Fund, Delos Capital and OrbiMed.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries A (as Exsilio Therapeutics)Jun 2024
$82.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Averna Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/averna-therapeutics"><img src="https://indexed.vc/api/badge/company/averna-therapeutics" alt="Averna Therapeutics on Indexed.vc" width="260" height="76" /></a>